Key result
Idarucizumab prevented excess intracerebral hematoma formation and significantly reduced mortality in a mouse model of dabigatran-related intracerebral hemorrhage.
Why the study?
Does idarucizumab reduce hematoma expansion and mortality in a mouse model of dabigatran-related intracerebral hemorrhage?
Does idarucizumab reduce hematoma expansion and mortality in a mouse model of dabigatran-related intracerebral hemorrhage?
Idarucizumab effectively reverses dabigatran-induced anticoagulation, reducing hematoma expansion and mortality in a murine model of intracerebral hemorrhage.
Answers are grounded in this paper and cite their sources.
Idarucizumab reversal should not yet alter practice in dabigatran-ICH; leaves open human efficacy trials.
Lack of specific antidotes is a major concern in intracerebral hemorrhage (ICH) related to direct anticoagulants including dabigatran (OAC-ICH). We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab. Pretreatment with DE increased intracerebral hematoma volume and cerebral hemoglobin content. Idarucizumab in equimolar dose prevented excess hematoma expansion for both DE doses. In more extensive ICH, idarucizumab significantly reduced mortality. Thus, idarucizumab prevents excess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.
No takes yet. Share an insight, caveat, or question.
Na et al. (2015) studied Intracerebral hemorrhage related to dabigatran. Idarucizumab was evaluated on Intracerebral hematoma volume, cerebral hemoglobin content, and mortality. Idarucizumab prevented excess intracerebral hematoma formation and significantly reduced mortality in a mouse model of dabigatran-related intracerebral hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: